-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Current prostate cancer screening guidelines conflict with the age at which screening begins.
study was conducted to assess the effects of prostate-specific antigen (PSA) screening and zero screening on prostate cancer mortality from the age of 50-54.
This is a population-based queue study that compared 3,479 50 yr to 54,54 who were randomly screened for PSA in a prostate cancer screening trial based on the G?teborg population, which was launched in 1995 yr males, with 4,060 51-55 yr un screened men who provided cryogenic blood preservation in the pre-PSA pre-era population-based Malm? prevention project between 1982 and 1985.
compared the cumulative incidence and morbidity of prostate cancer diagnosis, metastasis and prostate cancer deaths.
17 years, regular PSA screening of men in their early 50s in Gothenburg more than tripled the risk of prostate cancer diagnosis compared to men not screened in Malmo (incidence was more than 2.56, 95% confidence interval (CI) 2.18,3 (0.02), but the risk of metastasis (IRR 0.43, 95% CI 0.22, 0.79) and prostate cancer death (IRR 0.29, 95% CI 0.11, 0.67) were significantly reduced.
cancer deaths per 10,000 men in the screening group decreased by 57 (95% CI 22,92).
, the number of people invited for PSA screening and the number needed to diagnose and prevent one prostate cancer death were 176 and 16, respectively.
In summary, the results of this study show that PSA screening for prostate cancer can reduce prostate cancer mortality in men aged 50-54 years, and that under similar follow-up, the number of invites and tests required to prevent one prostate cancer death is comparable to the mortality rate of prostate cancer in men aged 55-69 reported in the previous European prostate cancer screening randomized study.
group may consider whether PSA screening guidelines should recommend starting no later than 50-54 years of age.
limitations of this study are the lack of treatment data and the comparison of two different birth queues.
.
